Trump Administration's Response to the Drug Crisis
PURPOSE
The hearing will examine ONDCPâs coordination of national drug control efforts, including the Administrationâs response to the opioid crisis. The hearing will also examine ONDCPâs implementation of the provisions of the SUPPORT for Patients and Communities Act that reauthorized the agency.
BACKGROUND
-
According to the Centers for Disease Control and Prevention (CDC), âIn 2017, there were 70,237 drug overdose deaths in the United States.â This is the highest rate of drug overdose deaths ever observed in the United States.
-
For two years, the Trump Administration had no drug control strategyâeven though the Administration was required by law to issue an annual strategy in both 2017 and 2018.
-
On January 31, 2019, the Trump Administration finally issued its first National Drug Control Strategy, but it was woefully inadequate and fails to comply with numerous provisions in the law.
-
For two years, the Trump Administration had no permanent ONDCP Director. James Carroll was confirmed on January 2, 2019, but appears to have little experience in drug control policy.
âChairman Cummings Opening Statement
The Honorable James W. Carroll, Jr.
Director, Office of National Drug Control Policy
Ms. Triana McNeil
Acting Director, Strategic Issues, Government Accountability Office
Mr. Mike McDaniel
Director, Houston High Intensity Drug Trafficking Area
- Notice
- Memo
- Attendance
- Cloud UC for the Record
- Ocasio-Cortez UC for the Record
- Annual Strategy Report - 2019
- Jordan UC
- Annual Strategy Report
- Questions for the Record - Response from Director Carroll
- QFR Supplemental Doc - Appendix to annual report
- Kinzinger Statement for the Record
- Jordan UC Washington Post Article